Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AR overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

AR amplification (5)

AR amplification (5)

›

AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
AR overexpression	Breast Cancer	AR overexpression	Breast Cancer	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3
AR overexpression	HER2 Positive Breast Cancer	AR overexpression	HER2 Positive Breast Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
AR overexpression	Estrogen Receptor Positive Breast Cancer	AR overexpression	Estrogen Receptor Positive Breast Cancer	EP0062 Sensitive: D – Preclinical EP0062 Sensitive : D	EP0062 Sensitive: D – Preclinical EP0062 Sensitive : D
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D
AR overexpression	Cholangiocarcinoma	AR overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D